Human CD14+ monocytes from rheumatoid arthritis patients before and after a 3-month period of Upadacitinib treatment
Janus Kinase (JAK) inhibitors are small molecules that reversibly inhibit JAK activity and their subsequent intracellular signaling and have become the treatment of choice for diseases with an inflammatory or immune basis. We explored the molecular impact of the JAK inhibitor Upadacitinib on the gene expression of human peripheral blood monocytes from three seropositive rheumatoid arthritis patients. The three patients showed disease improvementatthree months follow-up. Overall design: mRNA profiles of human peripheral blood CD14+ monocytes from rheumatoid arthritis patients at baseline and three months after Upadacitinib treatment